Amicus Therapeutics Q2 2024 Adj. EPS $0.06 Beats $(0.06) Estimate, Sales $126.669M Beat $121.244M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics (NASDAQ:FOLD) reported Q2 2024 adjusted EPS of $0.06, significantly beating the analyst estimate of $(0.06). The company also reported sales of $126.669 million, surpassing the $121.244 million estimate. This represents a 185.71% increase in EPS and a 34.04% increase in sales compared to the same period last year.
August 08, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amicus Therapeutics reported Q2 2024 adjusted EPS of $0.06, beating the analyst estimate of $(0.06) by 200%. Sales of $126.669 million also exceeded expectations, marking a 34.04% increase year-over-year.
The significant beat on both EPS and sales estimates, along with substantial year-over-year growth, is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100